Evidence map›Paper›PMID 41102952›Full record

ReviewCurrent pharmaceutical design2026

PANoptosis in Cytokine Release Syndrome: Bridging the Gap between Inflammation and Cell Death.

Lina Eltaib, Mashael N Alanazi, Yumna Khan, Ali Hanbashi, Gyas Khan, Hind A Rikabi, Mudasir Maqbool, Md Sadique Hussain

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lina EltaibDepartment of Pharmaceutics, College of Pharmacy, Northern Border University, Rafha, Saudi Arabia.ORCID 0000-0001-8885-7903
Mashael N AlanaziDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia.ORCID 0009-0001-0726-6560
Yumna KhanInstitute of Biotechnology and Genetic Engineering (Health Division), The University of Agriculture, Peshawar, 25000, Khyber Pakhtunkhwa, Pakistan.ORCID 0009-0008-5951-3691
Ali HanbashiDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0009-0008-1634-1850
Gyas KhanDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, 45142, Saudi Arabia.ORCID 0000-0003-2695-7401
Hind A RikabiDepartment of Clinical Pharmacy, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia.ORCID 0000-0001-7106-3517
Mudasir MaqboolDepartment of Pharmaceutical Sciences, University of Kashmir, Hazratbal, Srinagar, 190006, Jammu and Kashmir, India.ORCID 0000-0002-9036-008X
Md Sadique HussainUttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Prem Nagar, Dehradun, Uttarakhand, 248007, India.ORCID 0000-0002-3554-1750

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytokine Release Syndrome (CRS) is a hyperinflammatory condition triggered by infections, immunotherapies, and systemic immune dysregulation. PANoptosis, a unique form of programmed inflammatory cell death that integrates pyroptosis, apoptosis, and necroptosis, has emerged as a key contributor to CRS pathogenesis. This review explores the mechanistic role of PANoptosis in CRS, with particular emphasis on immunotherapy-induced toxicity and viral infections such as SARS-CoV-2 and influenza. PANoptosis exacerbates cytokine storms through ZBP1, NLRP3, and CASP8-mediated pathways, creating a pathological feedback loop that intensifies inflammation and promotes multi-organ damage. Current evidence suggests that modulating PANoptotic pathways, including targeting TNF-α, IFN-γ, and inflammasome components, may mitigate cytokine-driven tissue injury. Despite growing interest, the therapeutic potential of PANoptosis remains underexplored. Advancing our understanding of PANoptosis and its interaction with cytokine signaling will be critical for developing effective interventions for CRS and improving outcomes in patients undergoing immunotherapy or battling severe infections.

Indexed as

Cell DeathCytokine Release SyndromeInflammationAnimalsCOVID-19CytokinesHumansImmunotherapyCytokinesCaspasecytokine stormIFN-γinflammatory cell deathpathological feedbackTNF-α

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.